Abstract: Objective Cisplatin exerts its cytotoxic effect through distinct DNA lesions, leading to peripheral neuropathy. The risk of sensory neuropathy is a common problem during cancer treatment with cisplatin, leading to somatic hyperalgesia. Yet, data focussing on cisplatin-induced impairment of the autonomic nervous system are limited. The present study was aimed to investigate the effect of recombinant human erythropoietin (rhEPO) on cisplatin-induced visceral hyperalgesia. Methods C57BL/6 mice were treated either with cisplatin (2 mg/kg, once per week) or with cisplatin (2 mg/kg, once per week) plus rhEPO (40 µg/kg, 3 times per week) for 8 weeks. Controls were treated with saline. To quantify the visceromotor response (VMR) at week 9, standardized electrodes were implanted into the external oblique musculature for electromyographic recordings. After that, animals were decapitated and dorsal root ganglia (DRG) was removed for transmission electron microscopy studies.
Introduction
Cisplatin is widely used in the treatment of solid tumors.
However, its high efficacy in cancer treatment is usually accompanied with severe neurotoxic side effects, affecting the peripheral nervous system. The sensory neuropathy is a common problem that often leads to therapy withdrawal. The paradoxical combination of sensory loss and reduction in nociceptive threshold results in a painful somatic hypersensitivity. Although an animal model of nociceptive peripheral neuropathy has been introduced [1] , data concerning cisplatin-dependent impairment of the autonomic nervous system and the strategies to circumvent the visceral neuropathy are scarce and mostly focussed on inhibiting sero-tonergic pathways [2] . There is growing evidence that cation channels are involved in the process of neuropathic pain due to cisplatin [3, 4] .
The precise mechanisms of cisplatin-induced neurotoxicity remain still unclear. Cisplatin exerts its cytotoxic effect through the interaction with cellular DNA and the formation of distinct platinum (Pt)-DNA adducts [5] . Accumulation and persistence of DNA adducts in the cell nucleus can lead to cell apoptosis [6, 7] . There is growing evidence that nuclei of DRG neurons are the primary targets of cisplatin-induced neurotoxicity [8, 9] . Recently, we have found that repeated exposure to cisplatin can lead to sensory neuropathy in wild type (DNA repair proficient) mice and more severely in knockout [xeroderma pigmentosum complementation group A deficient (XPA -/-), xeroderma pigmentosum complementation group C deficient (XPC -/-), DNA repair deficient] mice [10] .
However, neurons in the spinal cord are protected by the intact blood-brain barrier, resulting in an approximately 40% decrease in Pt-DNA adducts [10] .
Moreover, accumulating evidence has indicated that recombinant human erythropoietin (rhEPO) possesses neuroprotective properties [11, 12] . In the peripheral nervous system, erythropoietin and its receptor are expressed in DRG neurons, axons and Schwann cells [13] . More recently, rhEPO has been demonstrated to produce neuroprotective effect against cisplatin-induced neurotoxicity, without affecting Pt-DNA adduct accumulation in DRG neurons [14] .
Cisplatin-induced significant impairment of sensory nerve function is associated with structural damage in somatic nerves and mitochondria. Administration of rhEPO can rescue the nerves from damage, consequently leading to significant improvement in electrophysiological parameters and a tendency toward improvement of the withdrawal threshold.
Besides, rhEPO does not have any effect on the nerve conduction velocity when administered alone [14] .
Based on our previous study on large myelinated somatic fibers, the present study was aimed to extend the un- c., Neorecormon ® , Roche, Basel, Switzerland) 3 times per week. These mice were injected with 500 µL saline i.p. as well to prevent renal damage. In group C, mice were only treated with saline (500 µL, i.p.) once per week as a control. In week 9, colorectal distension was conducted in all the groups. After that, mice were sacrificed and DRGs were removed from thoracic and lumbar regions for histological analysis. Since erythropoietin administration does not affect the peripheral nervous system [15, 16] , a fourth group was abdicated to minimize the number of experimental animals. (Fig. 1 ). This procedure was performed once in each animal. The applied distension protocol had been established in previous studies [17] and validated via ramp distension protocols. The EMG signal was amplified with the by the factor 100 000 and filtered with a band-pass filter with a high selectivity at a centre frequency of 120 Hz. An integrated EMG response was used as the response parameter and VMR was calculated as the area under the curve (AUC) using the ISOLAB software.
Study design

Assessment of VMR
Distension protocol
Electron microscopic examination of DRG neurons
DRGs were removed after colorectal distension and fixed in All sections were blinded, i.e., the examiner had no knowledge of whether the sections for evaluation were from control or tested group.
Statistical analysis
Data were presented as mean±SEM.
The differences of VMR between groups were evaluated by analysis of variance (ANOVA) with Bonferroni correction to control for type I error. All P values calculated were twotailed. P < 0.05 was considered as statistically significant. All further (exploratory) analyses were considered significant at an α-level of 5%. All statistical analyses were made using the SPSS software package (version 12.0.1, Chicago, Illinois, USA).
Results
Effect of rhEPO on cisplatin-altered visceral nociception
As shown in 
Histopathological findings
The neurotoxic side effect of cisplatin is based on Pt-DNA adduct accumulation in neurons of DRG [8] . Still, in vivo models to prove Pt-DNA adductdependent cell damage in DRG neurons are limited, as well as the proof of neuronal cell damage. Here the transmission electron microscope was employed to estimate the potential cellular damage in DRG neurons due to repeated cisplatin exposure. The spinal cord was not screened due to the intact blood-brain barrier that provides natural protection against toxic agents [10] . The morphological alteration of the nuclear membrane was detected in DRG neurons in cisplatin group (approximately 30% in each animal), with distinct kinking of the membrane (Fig. 3) . However, these distinct structural lesions were absent in DRG cells in the other 2 groups. 
Discussion
In the present study, we used an animal model to quantify cisplatin-induced visceral neuropathy, and rhEPO was shown to be an attractive compound to counteract cisplatininduced visceral neuropathy in mice. Besides, the attenuation of VMR was associated with the lack of structural lesions in the nuclear membrane, and cisplatin-induced visceral neuropathy was accompanied by the damage in neuronal tissue. It has been revealed that cisplatin primarily targets the DRG cells in the nervous system and loss of function or apoptosis of DRG cells is a hallmark of sensory neuropathy [18] .
Postmortem analysis of neuronal tissues from patients treated with cisplatin revealed high concentrations of platinum in the DRG [19] . Recently, augmented levels of platination products in the nuclear DNA of DRG neurons have been observed, which confirm the former results [8] . In a recent study, we showed a significant correlation between the amount of persisting DNA lesions and the degree of cisplatin-induced sensory neuropathy [10] . Our results support the hypothesis that DNA lesions are a risk factor for impairment of peripheral nerves.
In the present study, the concomitant administration of rhEPO led to significant attenuation of cisplatin-induced VMR enhancement and neuronal tissue damage. The effect of rhEPO on cisplatin-induced neurotoxicity had been demonstrated previously [20] . Here no difference in sensory nerve conduction velocity was found between control and cisplatin+rhEPO groups. Our previous study has confirmed the neuroprotective effect of rhEPO on drug-induced neuropathy with special emphasis on DNA-adduct formation in DRG neurons, and there is also no difference between control and cisplatin+rhEPO groups [14] . Apparently, the Pt-DNA adduct accumulation is not affected by rhEPO, thus the neuroprotective property of rhEPO is mediated rather by improved cell survival than by attenuation of Pt-DNA adduct formation. Our observations are in line with the hypothesis that Pt-DNA adducts lead to nuclear damage and consecutively to cell death.
In the peripheral nervous system, erythropoietin and its receptor are expressed in DRG neurons [11] . Erythropoietinmediated cytoprotective pathways involve proteins of BCL-2 family, extracellular signal-regulated kinases and phosphatidylinositol 3-kinase/Akt [21] . In neuronal cells, the nuclear transcription factor NF-κB is known to be affected by free radicals and cytokines [22] [23] [24] [25] . Binding of erythropoietin to its receptor leads to the activation of the phosphatidylinositol 3-kinase/Akt pathway and NF-κB pathway. The antiapoptotic proteins including XIAP and C-IAP2 are upregulated subsequently, blocking the activation of specific cell-death proteases [26] . More recently, it has been shown that erythropoietin mediates regeneration of adult neurons in the central nervous system via JAK2 and phosphatidylinositol 3-kinase/ Akt pathway [27] .
The neurotoxic side effect of cisplatin is still a challenging problem of cancer treatment. Most commonly, a dose reduction or even discontinuation of therapy is required due to the chronic discomfort in patients caused by the neurotoxic side effects. The prevalence of therapy withdrawal ranges between 30%-50% [28, 29] . The sensory neuropathy that causes chronic discomfort in patients remains a challenge for physicians. Recently, we have demonstrated a possible strategy to counteract cisplatin-induced neurotoxicity, with respect to nerve conduction velocity, somatic hypersensitivity and morphological changes in neuronal tissues [14] .
In conclusion, here we present data quantifying cisplatin- 
